Immunotherapy before bladder surgery for cisplatin-ineligible patients
Treatments studied
Part of Cancer clinical trials.
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18) and can sign consent
- You have muscle-invasive urothelial cancer confirmed by biopsy or urine testing
- Your cancer needs surgery that can fully remove it (R0 removal) with cure intent
- You cannot take cisplatin chemotherapy due to health reasons, or you chose not to
- You must be well enough for surgery, including good energy/activity level (ECOG 0–1) and adequate lung function tests
- Recent blood tests and organ tests (kidney, liver, blood counts) must be within required limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests atezolizumab (an immune therapy) given before surgery for certain bladder or upper urinary tract cancers. The goal is to shrink or control the cancer early and improve outcomes after curative surgery.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests a dense schedule of two chemotherapy drugs (gemcitabine and cisplatin) given before bladder removal surgery. It aims to shrink the tumor and improve outcomes for people with bladder cancer that has grown into the muscle layer.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Metastatic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.